MX2014007312A - Metodos para el tratamiento y la prevencion de estreñimiento inducido por opioides usando composiciones orales de metilnaltrexona. - Google Patents

Metodos para el tratamiento y la prevencion de estreñimiento inducido por opioides usando composiciones orales de metilnaltrexona.

Info

Publication number
MX2014007312A
MX2014007312A MX2014007312A MX2014007312A MX2014007312A MX 2014007312 A MX2014007312 A MX 2014007312A MX 2014007312 A MX2014007312 A MX 2014007312A MX 2014007312 A MX2014007312 A MX 2014007312A MX 2014007312 A MX2014007312 A MX 2014007312A
Authority
MX
Mexico
Prior art keywords
subject
mntx
methylnaltrexone
pharmaceutical composition
treatment
Prior art date
Application number
MX2014007312A
Other languages
English (en)
Spanish (es)
Inventor
Enoch Bortey
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of MX2014007312A publication Critical patent/MX2014007312A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2014007312A 2011-12-19 2012-12-19 Metodos para el tratamiento y la prevencion de estreñimiento inducido por opioides usando composiciones orales de metilnaltrexona. MX2014007312A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577654P 2011-12-19 2011-12-19
PCT/US2012/070612 WO2013096444A1 (en) 2011-12-19 2012-12-19 Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone

Publications (1)

Publication Number Publication Date
MX2014007312A true MX2014007312A (es) 2014-08-27

Family

ID=48669445

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007312A MX2014007312A (es) 2011-12-19 2012-12-19 Metodos para el tratamiento y la prevencion de estreñimiento inducido por opioides usando composiciones orales de metilnaltrexona.

Country Status (11)

Country Link
US (2) US20130317050A1 (enExample)
EP (1) EP2793888A4 (enExample)
JP (2) JP2015501849A (enExample)
KR (1) KR20140107540A (enExample)
CN (2) CN104254332A (enExample)
AU (3) AU2012359013A1 (enExample)
BR (1) BR112014014805A2 (enExample)
CA (1) CA2859203C (enExample)
IL (1) IL233266A0 (enExample)
MX (1) MX2014007312A (enExample)
WO (1) WO2013096444A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
WO2016061531A1 (en) * 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
JP2019513355A (ja) * 2016-03-29 2019-05-30 コロナリーコンセプツ エルエルシー 便秘症を処置するための製剤
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP1494683A1 (en) * 2002-04-05 2005-01-12 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
SE0303135D0 (sv) * 2003-11-25 2003-11-25 Lipocore Holding Ab Controlled food effect composition
US20070010543A1 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
EA201001643A1 (ru) * 2008-05-07 2011-06-30 Нектар Терапеутикс Пероральное введение периферически действующих опиоидных антагонистов
CN101845047B (zh) * 2009-12-31 2011-12-07 南京臣功制药有限公司 一种溴甲基纳曲酮的制备方法
SG10201501821RA (en) * 2010-03-11 2015-05-28 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone

Also Published As

Publication number Publication date
CA2859203A1 (en) 2013-06-27
IL233266A0 (en) 2014-08-31
CN104254332A (zh) 2014-12-31
US20130317050A1 (en) 2013-11-28
AU2019203694A1 (en) 2019-06-20
BR112014014805A2 (pt) 2017-06-13
US20190231771A1 (en) 2019-08-01
EP2793888A1 (en) 2014-10-29
AU2012359013A1 (en) 2014-06-26
KR20140107540A (ko) 2014-09-04
AU2017258808A1 (en) 2017-11-23
JP2019048820A (ja) 2019-03-28
JP2015501849A (ja) 2015-01-19
CA2859203C (en) 2020-08-25
CN110384701A (zh) 2019-10-29
NZ625863A (en) 2016-11-25
EP2793888A4 (en) 2015-10-28
WO2013096444A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
AU2009201019B2 (en) Dosage form containing oxycodone and naloxone
US20190231771A1 (en) Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
TW201141479A (en) Oral formulations and lipophilic salts of methylnaltrexone
KR20130106431A (ko) 파킨슨병의 치료에 있어서 오피오이드 효능제와 오피오이드 길항제의 조합물
TW202308653A (zh) 以神經活性類固醇進行治療的方法
NZ625863B2 (en) Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
WO2015191686A1 (en) Methods of administering methylnaltrexone
HK1219669B (en) Dosage form containing oxycodone and naloxone
HK1111604B (en) Dosage form containing oxycodone and naloxone
HK1168000A (en) Administration of intravenous ibuprofen
BR102013032395A2 (pt) Composição farmacêutica oral estável